MicroRNA intelligence
Read a regulatory control layer that sits upstream of many traditional biomarkers and connects research across multiple disease domains.
See how it worksPreventive health powered by microRNA intelligence
See change sooner. Extend healthspan.
miRoncol is building a microRNA intelligence platform to make preventive health earlier, more personal and more informed. It begins with miCheckup, its multi-cancer early detection test, and is designed to learn over time across four major chronic disease domains: cancer, cardiovascular, neurodegenerative and metabolic disease.
Published foundation
Oncology
miCheckup · early cancer detection
Detection research
Cardiovascular
Heart and vascular disease
Detection research
Neurodegenerative
Neurological decline
Detection research
Metabolic
Metabolic dysfunction
One microRNA intelligence platformFour major chronic disease domains
miCheckup
An Early Cancer Detection Test grounded in the first peer-reviewed publication of a miRNA-based multi-cancer early detection model.
See the miCheckup Cancer TestHealth over time
Begin while healthy, establish a personal molecular history and add context to change, intervention and response.
Understand the historyWhy prevention starts early
You cannot recreate a healthy baseline later.
Capturing a molecular profile while a person feels well creates a reference for recognizing future change. If that history does not yet exist, a single sample can still be analyzed for a disease-associated pattern present now.
Current-state intelligence
What molecular pattern is present today?
Longitudinal intelligence
How has that pattern changed from personal health?
“A single test captures the moment. Longitudinal intelligence helps us understand the change.”
Victoria Xu
Co-Founder & Chief Executive Officer, miRoncol Health
The Nobel Prize · 60-second explainer
The foundational science behind the platform.
The 2024 Nobel Prize in Physiology or Medicine recognized the discovery of microRNA and its role in post-transcriptional gene regulation. This independent video explains the biological control layer miRoncol is learning to read.
Explore the deeper science Independent scientific education from the Nobel Prize. The Nobel Prize does not endorse miRoncol or its products.A published research foundation
Peer-reviewed science. A focused first application.
miRoncol’s platform direction begins with published research in blood-based microRNA patterns for multi-cancer detection. miCheckup translates that foundation into the company’s first focused application.
Cancers2022
Detection of twelve common cancers using serum microRNA expression profiles
Peer-reviewed research investigating serum microRNA signatures across twelve cancer types.
Read the paperScientific Reports2024
Noninvasive multi-cancer detection using blood-based cell-free microRNAs
A peer-reviewed study examining whether microRNA patterns in blood could distinguish multiple cancers from non-cancer samples.
Read the paperFirst focused applicationmiCheckup
An Early Cancer Detection Test grounded in the first peer-reviewed publication of a miRNA-based multi-cancer early detection model.
miCheckup is miRoncol’s first focused application, informed by studies published in Scientific Reports and Cancers.
Visit the miCheckup Cancer TestA branching platform
One intelligence platform. Four major chronic disease domains.
miRoncol is focusing its research on four major chronic disease domains that shape healthspan: cancer, cardiovascular disease, neurodegenerative disease and metabolic disease. The evidence, research questions and stage of development differ by application.
miR
Shared intelligence core
Broad microRNA measurement, AI-assisted pattern recognition and longitudinal context.
Oncology
The research foundation behind miRoncol’s multi-cancer early detection test, miCheckup.
See the miCheckup Early Cancer Detection TestCardiovascular
Regulatory patterns connected to vascular biology, cardiac stress and inflammation.
Neurodegenerative
Patterns under investigation in neurological decline and neuroinflammatory biology.
Metabolic
Regulatory pathways connected to insulin response, energy balance and metabolic dysfunction.
Scientific discipline matters: these directions are not presented as equally validated products. Each moves forward only as the evidence supports it.
A platform designed to keep learning
Capture broadly today. See more tomorrow.
Beginning with comprehensive sequencing preserves the ability to ask new questions of earlier measurements as research and analytical models advance.
Capture the whole measured panel.
Build a broad molecular record that extends beyond the signals we know to look for today.
Return with better vision.
Apply evolving pattern-recognition models to investigate when a newly understood signal emerged and how it changed.
Measure a known signature.
Translate selected signatures into more focused assays for specific research and future applications.
“NGS preserves the possibilities. PCR provides the focus. Longitudinal data creates the history.”Christopher M. Gallagher, MD Co-Founder & Chief Medical Officer · Medical Oncologist
Why miRoncol
A team built to move from molecular research to preventive health.
Scientific, medical and company leadership working together around one question: what becomes possible when health is measured earlier and understood over time?
Make earlier prevention against the diseases that shorten healthspan accessible to everyone.
We envision a future where people can recognize meaningful biological change before symptoms appear and act earlier to protect more healthy years.
Build microRNA intelligence for preventive health.
Use convenient biological samples, AI-assisted pattern recognition and longitudinal data to recognize meaningful change earlier. Translate validated signals into focused tests.
Victoria Xu
Co-Founder & Chief Executive Officer
Entrepreneur and investor with graduate training in bioinformatics and public management, leading the platform from research toward preventive-health applications.
Christopher M. Gallagher, MD
Co-Founder & Chief Medical Officer
Practicing medical oncologist with more than 20 years in cancer care and clinical research, guiding clinical strategy and scientific rigor.
Gilles Erb, PhD
Medical & Scientific Director
Former Global Scientific Director for Integrated Molecular Medicine at Roche (FMI), with more than 20 years in oncology diagnostics and clinical validation.
Hai Hu, PhD
Co-Founder & Chief Scientific Officer
Award-winning bioinformatics scientist behind miRoncol’s peer-reviewed blood-based microRNA models for multi-cancer early detection.
Follow the work as it develops.
Request company updates
Company milestones, research progress, partnerships and perspectives from the miRoncol team.
Start earlier. Understand change. Protect more healthy years.
Explore the deeper microRNA intelligence platform story or visit the miCheckup early cancer detection test.